IONIS PHARMACEUTICALS INC 8-K

What Happened

• On July 9, 2026, Ionis Pharmaceuticals (with partner AstraZeneca) announced that the CARDIO‑TTRansform Phase 3 trial of eplontersen in transthyretin‑mediated amyloid cardiomyopathy (ATTR‑CM) did not meet the trial’s primary efficacy endpoint — the composite of cardiovascular (CV) mortality and recurrent CV clinical events through Week 140 versus placebo. The company furnished a press release as Exhibit 99.1 to its Form 8‑K.

Key Details

• Trial: CARDIO‑TTRansform, Phase 3, randomized, double‑blind, placebo‑controlled for ATTR‑CM; results announced July 9, 2026.
• Primary endpoint: No statistically significant benefit on composite outcome of CV mortality + recurrent CV events up to Week 140 versus placebo.
• Subgroup findings: In a prespecified subgroup comparing eplontersen monotherapy to placebo, a nominal hazard ratio of 0.71 was observed on the composite outcome; no treatment effect was seen in patients on transthyretin stabilizer therapy at baseline.
• Patient background and effects: 57% of patients in each arm were on a stabilizer at baseline and an additional 24% in each arm started a stabilizer during the trial. Secondary, imaging, and biomarker analyses favored eplontersen; large, sustained reductions in transthyretin were observed. Safety profile was consistent with prior data and described as favorable.
• Next steps: Ionis and AstraZeneca will continue analyzing the full data set and plan to present results at the European Society of Cardiology (ESC) Congress in August 2026.

Why It Matters

• For investors, the failure to meet the primary endpoint is material: it affects the immediate clinical and commercial outlook for eplontersen in ATTR‑CM and could influence regulatory and partnership plans. Positive secondary and subgroup signals (including transthyretin lowering and a nominal HR of 0.71 in monotherapy patients) indicate there may be nuance in the data, but these do not change the primary result. Expect further detail from the full dataset and the planned ESC presentation in August 2026.